Scher HI - Search Results

1

Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI. Danila DC, et al. Among authors: scher hi. Clin Cancer Res. 2007 Dec 1;13(23):7053-8. doi: 10.1158/1078-0432.CCR-07-1506. Clin Cancer Res. 2007. PMID: 18056182

2

Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.

Scher HI, Curley T, Yeh S, Tong W, O'Moore PV, Larson S. Scher HI, et al. Adv Exp Med Biol. 1992;324:115-29. doi: 10.1007/978-1-4615-3398-6_12. Adv Exp Med Biol. 1992. PMID: 1283494 Review. No abstract available.

3

Therapeutic alternatives for hormone-refractory prostatic cancer.

Scher HI, Curley T, Yeh S, Iversen JM, O'Dell M, Larson SM. Scher HI, et al. Semin Urol. 1992 Feb;10(1):55-64. Semin Urol. 1992. PMID: 1373515 Review.

4

Spinal epidural tumor in patients with prostate cancer. Clinical and radiographic predictors of response to radiation therapy.

Zelefsky MJ, Scher HI, Krol G, Portenoy RK, Leibel SA, Fuks ZY. Zelefsky MJ, et al. Among authors: scher hi. Cancer. 1992 Nov 1;70(9):2319-25. doi: 10.1002/1097-0142(19921101)70:9<2319::aid-cncr2820700918>3.0.co;2-8. Cancer. 1992. PMID: 1394060

5

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Among authors: scher hi. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

6

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L, et al. Scher HI, et al. J Clin Oncol. 1990 Nov;8(11):1830-8. doi: 10.1200/JCO.1990.8.11.1830. J Clin Oncol. 1990. PMID: 1700078

7

Prostatic cancer: where do we go from here?

Scher H. Scher H. Curr Opin Oncol. 1991 Jun;3(3):568-74. Curr Opin Oncol. 1991. PMID: 1892925 Review.

8

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.

Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N, et al. Sternberg CN, et al. Among authors: scher hi. Cancer. 1989 Dec 15;64(12):2448-58. doi: 10.1002/1097-0142(19891215)64:12<2448::aid-cncr2820641209>3.0.co;2-7. Cancer. 1989. PMID: 2819654

9

Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: a trial with 10-ethyl-deaza-aminopterin.

Schultz PK, Kelly WK, Begg C, Liebertz C, Cohen L, Scher HI. Schultz PK, et al. Among authors: scher hi. Urology. 1994 Aug;44(2):237-42. doi: 10.1016/s0090-4295(94)80138-x. Urology. 1994. PMID: 7519382 Free article. Clinical Trial.

10

Prostate cancer: improving the therapeutic index.

Scher HI. Scher HI. Semin Oncol. 1994 Oct;21(5):688-93. Semin Oncol. 1994. PMID: 7524157 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

698 results

Search Page

Filters